![Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK's Breo Ellipta generics • NCK Pharma Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK's Breo Ellipta generics • NCK Pharma](https://nckpharma.com/wp-content/uploads/2018/11/breo_ellipta.jpg)
Hikma Pharmaceuticals and Vectura codevelopment and commercialization of GSK's Breo Ellipta generics • NCK Pharma
![BREO ELLIPTA Market Exclusivity Period (MEP). When do the BREO ELLIPTA patents expire, and when will generic BREO ELLIPTA be available? BREO ELLIPTA Market Exclusivity Period (MEP). When do the BREO ELLIPTA patents expire, and when will generic BREO ELLIPTA be available?](https://www.drugpatentwatch.com/p/graph/s/t/BREO+ELLIPTA-patent-expirations.png)
BREO ELLIPTA Market Exclusivity Period (MEP). When do the BREO ELLIPTA patents expire, and when will generic BREO ELLIPTA be available?
![Hikma and Vectura to Produce Generic Versions of GSK's Ellipta Meds - Pharmaceutical Processing World Hikma and Vectura to Produce Generic Versions of GSK's Ellipta Meds - Pharmaceutical Processing World](https://pharmaceuticalprocessingworld.com/wp-content/uploads/2019/10/ddd1707_COPD.jpg)
Hikma and Vectura to Produce Generic Versions of GSK's Ellipta Meds - Pharmaceutical Processing World
![As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma As Advair struggles, GlaxoSmithKline seeks expanded label for blockbuster-to-be Trelegy | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/FiercePharma-1511795226/trelegy.png?VersionId=9ZF.d_etbLV7zCq2is7cCwUDiksDCDFI)